Equillium, a biotech startup developing treatments for immune system disorders-including an immune response that affects some transplant recipients-is preparing for an IPO to finance tests of its lead drug.
The company set a preliminary IPO target of $86 million, according to documents filed this week with securities regulators, and has applied to be listed on the Nasdaq exchange under the stock symbol “EQ.”
La Jolla, CA-based Equillium, founded in 2017 (originally as Attenuate Biopharmaceuticals), licensed its antibody drug candidate itolizumab (which it calls EQ001) from Biocon Limited (NSE: BIOCON), India’s largest biopharmaceutical company. Itolizumab has been approved in India to… Read more »
UNDERWRITERS AND PARTNERS